Site specific modification of the human plasma proteome by methylglyoxal

Michael J. Kimzey, Owen R. Kinsky, Hussein N. Yassine, George Tsaprailis, Craig S Stump, Terrence Monks, Serrine Lau

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Increasing evidence identifies dicarbonyl stress from reactive glucose metabolites, such as methylglyoxal (MG), as a major pathogenic link between hyperglycemia and complications of diabetes. MG covalently modifies arginine residues, yet the site specificity of this modification has not been thoroughly investigated. Sites of MG adduction in the plasma proteome were identified using LC-MS/MS analysis in vitro following incubation of plasma proteins with MG. Treatment of plasma proteins with MG yielded 14 putative MG hotspots from five plasma proteins (albumin [nine hotspots], serotransferrin, haptoglobin [2 hotspots], hemopexin, and Ig lambda-2 chain C regions). The search results revealed two versions of MG-arginine modification, dihydroxyimidazolidine (R + 72) and hydroimidazolone (R + 54) adducts. One of the sites identified was R257 in human serum albumin, which is a critical residue located in drug binding site I. This site was validated as a target for MG modification by a fluorescent probe displacement assay, which revealed significant drug dissociation at 300 μM MG from a prodan-HSA complex (75 μM). Moreover, twelve human plasma samples (six male, six female, with two type 2 diabetic subjects from both genders) were analyzed using multiple reaction monitoring (MRM) tandem mass spectrometry and revealed the presence of the MG-modified albumin R257 peptide. These data provide insights into the nature of the site-specificity of MG modification of arginine, which may be useful for therapeutic treatments that aim to prevent MG-mediated adverse responses in patients.

Original languageEnglish (US)
Pages (from-to)155-162
Number of pages8
JournalToxicology and Applied Pharmacology
Volume289
Issue number2
DOIs
StatePublished - Dec 1 2015

Fingerprint

Pyruvaldehyde
Plasma (human)
Proteome
Arginine
Blood Proteins
Serum Albumin
Albumins
Hemopexin
Haptoglobins
Diabetes Complications
Transferrin
Medical problems
Metabolites
Tandem Mass Spectrometry
Fluorescent Dyes
Hyperglycemia
Pharmaceutical Preparations
Mass spectrometry
Assays

Keywords

  • Adducts
  • Glyco-oxidation
  • Methylglyoxal
  • Proteomics
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology

Cite this

Site specific modification of the human plasma proteome by methylglyoxal. / Kimzey, Michael J.; Kinsky, Owen R.; Yassine, Hussein N.; Tsaprailis, George; Stump, Craig S; Monks, Terrence; Lau, Serrine.

In: Toxicology and Applied Pharmacology, Vol. 289, No. 2, 01.12.2015, p. 155-162.

Research output: Contribution to journalArticle

@article{556478b7152c42ada40f48c0846ded39,
title = "Site specific modification of the human plasma proteome by methylglyoxal",
abstract = "Increasing evidence identifies dicarbonyl stress from reactive glucose metabolites, such as methylglyoxal (MG), as a major pathogenic link between hyperglycemia and complications of diabetes. MG covalently modifies arginine residues, yet the site specificity of this modification has not been thoroughly investigated. Sites of MG adduction in the plasma proteome were identified using LC-MS/MS analysis in vitro following incubation of plasma proteins with MG. Treatment of plasma proteins with MG yielded 14 putative MG hotspots from five plasma proteins (albumin [nine hotspots], serotransferrin, haptoglobin [2 hotspots], hemopexin, and Ig lambda-2 chain C regions). The search results revealed two versions of MG-arginine modification, dihydroxyimidazolidine (R + 72) and hydroimidazolone (R + 54) adducts. One of the sites identified was R257 in human serum albumin, which is a critical residue located in drug binding site I. This site was validated as a target for MG modification by a fluorescent probe displacement assay, which revealed significant drug dissociation at 300 μM MG from a prodan-HSA complex (75 μM). Moreover, twelve human plasma samples (six male, six female, with two type 2 diabetic subjects from both genders) were analyzed using multiple reaction monitoring (MRM) tandem mass spectrometry and revealed the presence of the MG-modified albumin R257 peptide. These data provide insights into the nature of the site-specificity of MG modification of arginine, which may be useful for therapeutic treatments that aim to prevent MG-mediated adverse responses in patients.",
keywords = "Adducts, Glyco-oxidation, Methylglyoxal, Proteomics, Type 2 diabetes mellitus",
author = "Kimzey, {Michael J.} and Kinsky, {Owen R.} and Yassine, {Hussein N.} and George Tsaprailis and Stump, {Craig S} and Terrence Monks and Serrine Lau",
year = "2015",
month = "12",
day = "1",
doi = "10.1016/j.taap.2015.09.029",
language = "English (US)",
volume = "289",
pages = "155--162",
journal = "Toxicology and Applied Pharmacology",
issn = "0041-008X",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Site specific modification of the human plasma proteome by methylglyoxal

AU - Kimzey, Michael J.

AU - Kinsky, Owen R.

AU - Yassine, Hussein N.

AU - Tsaprailis, George

AU - Stump, Craig S

AU - Monks, Terrence

AU - Lau, Serrine

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Increasing evidence identifies dicarbonyl stress from reactive glucose metabolites, such as methylglyoxal (MG), as a major pathogenic link between hyperglycemia and complications of diabetes. MG covalently modifies arginine residues, yet the site specificity of this modification has not been thoroughly investigated. Sites of MG adduction in the plasma proteome were identified using LC-MS/MS analysis in vitro following incubation of plasma proteins with MG. Treatment of plasma proteins with MG yielded 14 putative MG hotspots from five plasma proteins (albumin [nine hotspots], serotransferrin, haptoglobin [2 hotspots], hemopexin, and Ig lambda-2 chain C regions). The search results revealed two versions of MG-arginine modification, dihydroxyimidazolidine (R + 72) and hydroimidazolone (R + 54) adducts. One of the sites identified was R257 in human serum albumin, which is a critical residue located in drug binding site I. This site was validated as a target for MG modification by a fluorescent probe displacement assay, which revealed significant drug dissociation at 300 μM MG from a prodan-HSA complex (75 μM). Moreover, twelve human plasma samples (six male, six female, with two type 2 diabetic subjects from both genders) were analyzed using multiple reaction monitoring (MRM) tandem mass spectrometry and revealed the presence of the MG-modified albumin R257 peptide. These data provide insights into the nature of the site-specificity of MG modification of arginine, which may be useful for therapeutic treatments that aim to prevent MG-mediated adverse responses in patients.

AB - Increasing evidence identifies dicarbonyl stress from reactive glucose metabolites, such as methylglyoxal (MG), as a major pathogenic link between hyperglycemia and complications of diabetes. MG covalently modifies arginine residues, yet the site specificity of this modification has not been thoroughly investigated. Sites of MG adduction in the plasma proteome were identified using LC-MS/MS analysis in vitro following incubation of plasma proteins with MG. Treatment of plasma proteins with MG yielded 14 putative MG hotspots from five plasma proteins (albumin [nine hotspots], serotransferrin, haptoglobin [2 hotspots], hemopexin, and Ig lambda-2 chain C regions). The search results revealed two versions of MG-arginine modification, dihydroxyimidazolidine (R + 72) and hydroimidazolone (R + 54) adducts. One of the sites identified was R257 in human serum albumin, which is a critical residue located in drug binding site I. This site was validated as a target for MG modification by a fluorescent probe displacement assay, which revealed significant drug dissociation at 300 μM MG from a prodan-HSA complex (75 μM). Moreover, twelve human plasma samples (six male, six female, with two type 2 diabetic subjects from both genders) were analyzed using multiple reaction monitoring (MRM) tandem mass spectrometry and revealed the presence of the MG-modified albumin R257 peptide. These data provide insights into the nature of the site-specificity of MG modification of arginine, which may be useful for therapeutic treatments that aim to prevent MG-mediated adverse responses in patients.

KW - Adducts

KW - Glyco-oxidation

KW - Methylglyoxal

KW - Proteomics

KW - Type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=84949198235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949198235&partnerID=8YFLogxK

U2 - 10.1016/j.taap.2015.09.029

DO - 10.1016/j.taap.2015.09.029

M3 - Article

C2 - 26435215

AN - SCOPUS:84949198235

VL - 289

SP - 155

EP - 162

JO - Toxicology and Applied Pharmacology

JF - Toxicology and Applied Pharmacology

SN - 0041-008X

IS - 2

ER -